GLP1R and Prader-Willi syndrome: Six identified publications reported hyperphagia-related outcomes in patients with HO or PWS who were treated with GLP-1R agonists [111–116]; 1 case study of a patient with BBS also reported BMI reduction with GLP-1R agonist treatment, but change in hyperphagia was not reported [117].